STEP – The lived experience of Parkinson’s disease
sponsored by UCB
Author: UCBPublished: 31 January 2018
Prep: Cook: Serves:
An innovative market research (“research”) programme, STEP™, aims to move beyond the focus on Parkinson’s symptoms to examine the real lived experience of Parkinson’s. We look at how the STEP™ programme sheds light on the impact of the condition on a person’s life, relationships and identity – and how it can help address the multiple dimensions of the condition
When people think of Parkinson’s, they are likely to think of the most widely recognised symptoms such as tremor and movement difficulties. But, as people living with the condition will emphasise, its impact goes much wider, affecting a person’s relationships and their sense of self.
A recent piece of research aimed to gain a fuller understanding of this impact. STEP™ was an innovative, ethnographic and context lab research programme undertaken in the UK, US and Canada. The programme included 63 people with Parkinson’s, between the ages of 40 and 76, who had lived with Parkinson’s for between six months and 21 years and had varied experiences of treatment. A total of 19 partners and those providing care, 18 healthcare professionals and other Parkinson’s experts also took part.
Researchers visited participants at home to glean first-hand experiences about living with the condition. People living with Parkinson’s and their loved ones were asked to speak freely about their experiences, and some also took part in group discussions where they shared the aspects that mattered most to them.
“People with Parkinson’s spoke freely about living with the condition”
The academics – who were anthropologists and strategists – also held in-depth one-to-one interviews with healthcare professionals and other experts who have frequent contact with people living with the condition, and visited the places where they interact.
The findings may not be that surprising to those familiar with Parkinson’s (see key insights from STEP™ research below), but researchers hope that this evidence-based research will help those who look after people with Parkinson’s to develop more appropriate and holistic approaches, with the confidence that they are addressing real needs. By giving a voice to people with Parkinson’s, STEP™ may well lead to solutions that improve how an individual views their experience of the condition.
Key insights from STEP™ research
In addition to key research insights, the findings suggest that people with Parkinson’s first experience the condition as a lifestyle disorder, then as intermittent periods of capability and loss, and finally as a loss of independence. Often forgotten in this are their loved ones who also experience a transition, with partners, friends and family members often becoming full-time caregivers as the condition progresses.
“By giving a voice to people with Parkinson’s, STEP™ may lead to better solutions”
Based on these insights, the following phases have been identified throughout the patient and loved-one or caregiver journey as Parkinson’s unfolds:
Pre-diagnosis – a person notices a ‘first sign’ such as a finger twitch. At first, these early symptoms are often rationalised as part of the natural ageing process.
Diagnosis – a moment of transition that alters a person’s understanding of their own physical health.
Lifestyle – a period of adjustment to a new way of life marked by mild to moderate limitations: Parkinson’s feels like a bother, not a disease.
Straddle – moving back and forth between pre-Parkinson’s life in “on” (medication is working and symptoms reduced) and glimpses of the disease in “off” moments (medication effect has worn off and symptoms become more severe).
Disease – after years of navigating “on” and “off” periods, the experience of Parkinson’s transforms into a ‘disease’ in the medical sense of the word. Unmanageable fluctuations, loss of independence, development of other conditions and medication side-effects begin to affect the patient’s entire personhood as they know it.
While every individual’s journey will be unique and complex, these common attributes allow those providing support to think about more than managing the physical symptoms. Incorporating the social, emotional and relationship aspects of living with Parkinson’s – and offering solutions as appropriate – can help both the person with Parkinson’s and their loved ones or caregivers to maximise positive outcomes along their journey. Ref: HQ/1217/NU/00088
UCB is a global biopharmaceutical company with a focus on neurology.
UCB is committed to identifying and addressing the unmet needs of people living with Parkinson’s disease to enable them to have a more engaged life every day.
This research was conducted by Idea Couture, now part of Cognizant Digital Works on behalf of UCB.
The authors thank the people living with Parkinson’s, and all other participants in addition to the researchers and their teams who contributed to this research.
STEP™ is a trademark of UCB Biopharma SPRL.
To access to the full report, please visit ucb.com.
This article is sponsored by UCB. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Watch: Icelandic football team takes to the pitch in Parkinson’s tops
Parkinson’s took centre stage in an international friendly against Ghana
4 days ago
Study suggests why neurons die in Parkinson’s disease
Researchers at the University of Córdoba, Spain, have discovered how a certain protein may be linked to death of dopamine-producing neurons associated with Parkinson’s. Using animal models of the condition to conduct their study, the team focused on the protein DJ-1 – whose link to Parkinson’s has previously been established, though its exact function was uncertain. The researchers compared neurons in the brains of mice that possessed the gene expressing DJ-1 with those that did not. The findings revealed that dysfunction or absence of the gene expressing the DJ-1 protein could trigger the ‘cell cycle’ (the process by which cells divide), which should not occur under normal conditions. Because neurons lack the capacity to divide, this causes them die – leading to the onset of symptoms linked with Parkinson’s. It is hoped that uncovering these details about the relationship between DJ-1’s absence and Parkinson’s may lead to the development of…
Researchers have finally identified brain cells linked to Parkinson’s disease
For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…
Tiny DBS implant shows potential to advance Parkinson’s disease treatment
In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”